1、 Clinton Health Access Initiative,Inc.Continental Market-shaping Strategy for a Sustainable Vaccine Manufacturing Footprint in Africa Vaccine Markets Team November 2023 Key Takeaways The inequitable rollout of COVID-19 vaccines drew global attention to the lack of vaccine manufacturing capacity in A

2、frica.Significant political and financial investment has now been made in African vaccine manufacturing,creating significant growth momentum behind the industry.Stakeholders in the global health ecosystem have three major objectives when it comes to the expansion of African vaccine manufacturing:imp

3、roved pandemic preparedness and response(PPR),robust global market health,and commercial viability of manufacturers.Our analysis offers a view on how to target a compromise between these objectives.Our target identifies a market-size of three to five geographically dispersed manufacturers within Afr

4、ica to meet these objectives.To provide comprehensive coverage during a potential pandemic,this manufacturing footprint should target end-to-end production capacity of approximately 170 million doses per annum across eight identified antigens and nearly 460 million doses per annum of additional anti

5、gen-agnostic Drug Product(DP)capacity.The current manufacturing landscape indicates four major risks to achieving this target:1.Vaccines are likely to be costly to produce initially,risking low uptake,due to structural cost disadvantages.2.The current footprint of African vaccine manufacturing excee

6、ds the target for DP capacity and annual African vaccine demand-with the majority of installed DP capacity sitting idle due to lack of tech transfers,while current Drug Substance(DS)capacity is far lower.3.Governments have taken limited steps to procure African-made vaccines,making future manufactur